Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

2.

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Beeton C, Pennington MW, Norton RS.

Inflamm Allergy Drug Targets. 2011 Oct;10(5):313-21. Review.

3.

Targeting effector memory T-cells with Kv1.3 blockers.

Wulff H, Pennington M.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):438-45. Review.

PMID:
17659485
4.

Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.

Norton RS, Pennington MW, Wulff H.

Curr Med Chem. 2004 Dec;11(23):3041-52. Review.

PMID:
15578998
5.

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.

Rangaraju S, Chi V, Pennington MW, Chandy KG.

Expert Opin Ther Targets. 2009 Aug;13(8):909-24. doi: 10.1517/14728220903018957. Review.

PMID:
19538097
6.

Potassium channels as therapeutic targets for autoimmune disorders.

Wulff H, Beeton C, Chandy KG.

Curr Opin Drug Discov Devel. 2003 Sep;6(5):640-7. Review.

PMID:
14579513
7.

Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.

Zhao Y, Huang J, Yuan X, Peng B, Liu W, Han S, He X.

Toxins (Basel). 2015 May 19;7(5):1749-64. doi: 10.3390/toxins7051749. Review.

8.

Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?

Wang J, Xiang M.

Pharmacotherapy. 2013 May;33(5):515-28. doi: 10.1002/phar.1236. Epub 2013 Apr 5. Review.

PMID:
23649812
9.

Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.

Valverde P, Kawai T, Taubman MA.

J Dent Res. 2005 Jun;84(6):488-99. Review.

PMID:
15914584
10.

The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.

Jensen BS, Hertz M, Christophersen P, Madsen LS.

Expert Opin Ther Targets. 2002 Dec;6(6):623-36. Review.

PMID:
12472376
11.

Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Ebert LM, Schaerli P, Moser B.

Mol Immunol. 2005 May;42(7):799-809. Epub 2004 Nov 23. Review.

PMID:
15829268
12.

Potassium channels, memory T cells, and multiple sclerosis.

Beeton C, Chandy KG.

Neuroscientist. 2005 Dec;11(6):550-62. Review.

PMID:
16282596
13.

K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.

Panyi G, Possani LD, Rodríguez de la Vega RC, Gáspár R, Varga Z.

Curr Pharm Des. 2006;12(18):2199-220. Review.

PMID:
16787250
14.

K+ channels as targets for specific immunomodulation.

Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD.

Trends Pharmacol Sci. 2004 May;25(5):280-9. Review.

15.

Use of Kv1.3 blockers for inflammatory skin conditions.

Nguyen W, Howard BL, Neale DS, Thompson PE, White PJ, Wulff H, Manallack DT.

Curr Med Chem. 2010;17(26):2882-96. Review.

16.

Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Kazama I.

J Physiol Sci. 2015 Jan;65(1):25-35. doi: 10.1007/s12576-014-0331-x. Epub 2014 Aug 6. Review.

PMID:
25096892
17.

Voltage-Gated Potassium Channels Kv1.3--Potentially New Molecular Target in Cancer Diagnostics and Therapy.

Teisseyre A, Gąsiorowska J, Michalak K.

Adv Clin Exp Med. 2015 May-Jun;24(3):517-24. doi: 10.17219/acem/22339. Review.

18.

Roles of lymphocyte kv1.3-channels in the pathogenesis of renal diseases and novel therapeutic implications of targeting the channels.

Kazama I.

Mediators Inflamm. 2015;2015:436572. doi: 10.1155/2015/436572. Epub 2015 Mar 18. Review.

19.

T cells in vascular inflammatory diseases.

Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH.

Front Immunol. 2014 Oct 14;5:504. doi: 10.3389/fimmu.2014.00504. eCollection 2014. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk